Drug intelligence / Profile preview

xininurad

Development stage: Phase 1
Lead developer: Evopoint Biosciences
Modality: Small Molecules
Administration: Oral

Overview

Xininurad (XNW3009) is an orally administered small molecule drug that acts as a selective inhibitor of the human urate transporter 1 (URAT1, also known as SLC22A12 protein). By inhibiting URAT1 in the kidneys, xininurad increases renal excretion of uric acid and lowers serum uric acid levels. It is being developed primarily for the treatment of hyperuricaemia and gout. The drug was originally developed by Sinovent and is currently being advanced by Evopoint Biosciences. Clinical trials have reached Phase II for gout and Phase III for hyperuricaemia.

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on xininurad.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xininurad.

Explore the full profile